Positive WB detected in | SH-SY5Y cells, HeLa cells,K-562 cells,C2C12 cells,Neuro-2a cells |
Positive IHC detected in | mouse brain tissue, human brain tissue,human brain (FTLD-U) tissue,human gliomas tissue,human pancreas tissue,rat brain tissueNote: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Positive IF detected in | HepG2 cells, HeLa cells,SH-SY5Y cells |
Positive FC detected in | HeLa cells |
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:2000-1:10000 |
Immunohistochemistry (IHC) | IHC : 1:1000-1:4000 |
Immunofluorescence (IF) | IF : 1:50-1:500 |
Sample-dependent, check data in validation data gallery |
KD/KO | See 15 publications below |
WB | See 464 publications below |
IHC | See 555 publications below |
IF | See 308 publications below |
IP | See 32 publications below |
ELISA | See 3 publications below |
CoIP | See 4 publications below |
ChIP | See 4 publications below |
RIP | See 2 publications below |
10782-2-AP targets TDP-43 inWB, RIP, IP, IHC, IF, IEM, FC, CoIP, chIP, ELISA applications and shows reactivity with human, mouse, rat, zebrafish samples.
Tested Reactivity | human, mouse, rat, zebrafish |
Cited Reactivity | C. elegans, chicken, dog, Drosophila, fly, hamster, horse, human, monkey, mouse |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | fusion protein |
Full Name | TAR DNA binding protein |
Calculated molecular weight | 43 kDa |
Observed molecular weight | 43 kDa |
GenBank accession number | BC001487 |
Gene symbol | TARDBP |
Gene ID (NCBI) | 23435 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.1% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for-20oC storage. |
The TARDBP gene encodes the TDP-43 protein, initially found to repress HIV-1 transcription by binding TAR DNA. TDP-43 has since been shown to bind RNA as well as DNA, and have multiple functions in transcriptional repression, translational regulation and pre-mRNA splicing. For instance, it is reported to regulate alternate splicing of the CTFR gene. In 2006 Neumann et al. found that hyperphosphorylated, ubiquitinated and/or cleaved forms of TDP-43, collectively known as pathological TDP-43, play a major role in the disease mechanisms of ubiquitin-positive, tau- and alpha-synuclein-negative frontotemporal dementia (FTLD-U) and in amyotrophic lateral sclerosis (ALS). Proteintech"s 10782-2-AP antibody is a rabbit polyclonal antibody recognizing N-terminal TDP-43. It recognizes the intact 43 kDa protein as well as all posttranslationally modified and truncated forms in multiple applications.Various forms of TDP-43 exist, including 18-35 kDa of cleaved C-terminal fragments, 45-50 kDa phospho-protein, 55 kDa glycosylated form, 75 kDa hyperphosphorylated form, and 90-300 kDa cross-linked form. (17023659, 19823856, 21666678, 22193176) Recently TDP-43 has been reported to be overexpressed in triple negative breast cancer (TNBC) and it may be a potential target for TNBC diagnosis and drug design. (29581274)
Product Specific Protocols | |
---|---|
WB protocol for TDP-43 antibody 10782-2-AP | Download protocol |
IHC protocol for TDP-43 antibody 10782-2-AP | Download protocol |
IF protocol for TDP-43 antibody 10782-2-AP | Download protocol |
FC protocol for TDP-43 antibody 10782-2-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Proteintech是一家以研发、生产、销售抗体/重组蛋白及相关 产品为主要业务的生物技术公司。拥有严格的抗体生产、质检质控体系,产品涵盖整个生命科学领域。Proteintech作为全球最大的专业抗体生产 商之一,凭借一支锐意进取的技术团队和稳定的技术平台,已研发和生产出14000多种特种抗体和14000多种人源蛋白产品。2018年4月正式收 购首家人源细胞生产人类蛋白的Humanzyme公司,新增Humankine高活性人源蛋白产品系列。目前,Proteintech已建立全球市场销售网络, 美国、欧洲、中国和日本均有现货库存,全球24小时现货发售。
2001
Proteintech在美国创立
2003.8
使用Proteintech产品的第一篇文献发表
2004
在中国武汉成立中国分公司;第100个抗体成功生产
2001
Proteintech在美国创立
2003.8
使用Proteintech产品的第一篇文献发表
2004
在中国武汉成立中国分公司;第100个抗体成功生产
2006.4
第一个单克隆抗体上线销售
2007
在英国曼彻斯特成立欧洲分公司;使用Proteintech产品的发表文章达到50篇
2008
使用Proteintech产品的发表文章达到100篇
2001
Proteintech在美国创立
2003.8
使用Proteintech产品的第一篇文献发表
2004
在中国武汉成立中国分公司;第100个抗体成功生产
2006.4
第一个单克隆抗体上线销售
2007
在英国曼彻斯特成立欧洲分公司;使用Proteintech产品的发表文章达到50篇
2008
使用Proteintech产品的发表文章达到100篇
2010
使用Proteintech产品的发表文章达到1000篇
2012.3.3
第一个ELISA试剂盒上线销售;欧洲分公司获得ISO9001认证
2013
新实验室成立;使用Proteintech产品的发表文章达到5000篇
2001
Proteintech在美国创立
2003.8
使用Proteintech产品的第一篇文献发表
2004
在中国武汉成立中国分公司;第100个抗体成功生产
2006.4
第一个单克隆抗体上线销售
2007
在英国曼彻斯特成立欧洲分公司;使用Proteintech产品的发表文章达到50篇
2008
使用Proteintech产品的发表文章达到100篇
2010
使用Proteintech产品的发表文章达到1000篇
2012.3.3
第一个ELISA试剂盒上线销售;欧洲分公司获得ISO9001认证
2013
新实验室成立;使用Proteintech产品的发表文章达到5000篇
2014
获得SPF鼠房认证以及ISO9001以及ISO13485认证
2015.1
内部siRNA部门正式成立;使用Proteintech产品的文章达到10000篇
2018
Proteintech acquires Humanzyme, manufacturer of human-cell expressed proteins.
2001
Proteintech在美国创立
2003.8
使用Proteintech产品的第一篇文献发表
2004
在中国武汉成立中国分公司;第100个抗体成功生产
2006.4
第一个单克隆抗体上线销售
2007
在英国曼彻斯特成立欧洲分公司;使用Proteintech产品的发表文章达到50篇
2008
使用Proteintech产品的发表文章达到100篇
2010
使用Proteintech产品的发表文章达到1000篇
2012.3.3
第一个ELISA试剂盒上线销售;欧洲分公司获得ISO9001认证
2013
新实验室成立;使用Proteintech产品的发表文章达到5000篇
2014
获得SPF鼠房认证以及ISO9001以及ISO13485认证
2015.1
内部siRNA部门正式成立;使用Proteintech产品的文章达到10000篇
2018
Proteintech acquires Humanzyme, manufacturer of human-cell expressed proteins.
现在
Proteintech的产品已经达到12000多种,通过直销以及授权分销体系,产品覆盖五大洲55个国家。